Abdominal Aortic Aneurysms and Pseudoexfoliation Syndrome

October 17, 2007 updated by: European Georges Pompidou Hospital

Abdominal Aortic Aneurysms Are Associated With Pseudoexfoliation Syndrome

Conflicting results have been reported concerning the association of pseudoexfoliation syndrome (PXF) and abdominal aortic aneurysms (AAA). Schumacher et al. reported an association between AAA and PXF, with no consideration of grade. However, a later study did not confirm the association between AAA and PXF. The present study aimed at comparing the relative prevalence of PXF in patients suffering from AAA and in age-matched hypertensive patients.

Study Overview

Status

Terminated

Conditions

Study Type

Observational

Enrollment (Actual)

208

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Locations

  • France
      • Paris, France, 75015
        • Hôpital Européen Georges Pompidou

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

60 years and older (Adult, Older Adult)

Accepts Healthy Volunteers

No

Genders Eligible for Study

All

Sampling Method

Non-Probability Sample

Study Population

in patients suffering from abdominal aortic aneurism as part of a routine clinical yearly follow-up and hypertensive patients without abdominal aortic aneurism and that were more than 60 years old to have similar mean ages in both groups, as pseudoexfoliation and abdominal aortic aneurism are age-related disorders

Description

Inclusion Criteria:

  • Presence of abdominal aortic aneurism
  • Systemic hypertension without abdominal aortic aneurism over 60 years old

Exclusion Criteria:

  • Unknown status for abdominal aortic aneurism

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

Cohorts and Interventions

Group / Cohort
AAA group, control group
AAA group : with AAA Control group: without AAA

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Time Frame
standard ophthalmologic examination to group patients according to their pseudoexfoliation status
Time Frame: Day of standard ophthalmologic examination
Day of standard ophthalmologic examination

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

European Georges Pompidou Hospital

Investigators

  • Study Director: Patrick Rossignol, MD, PhD

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start

December 1, 2001

Study Completion (Actual)

July 1, 2002

Study Registration Dates

First Submitted

October 17, 2007

First Submitted That Met QC Criteria

October 17, 2007

First Posted (Estimate)

October 18, 2007

Study Record Updates

Last Update Posted (Estimate)

October 18, 2007

Last Update Submitted That Met QC Criteria

October 17, 2007

Last Verified

October 1, 2007

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • 01 (Miami VAHS)

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Hypertension

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Rwanda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe